Guy Neff

11.1k total citations · 7 hit papers
141 papers, 4.9k citations indexed

About

Guy Neff is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Guy Neff has authored 141 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Hepatology, 73 papers in Epidemiology and 45 papers in Surgery. Recurrent topics in Guy Neff's work include Liver Disease Diagnosis and Treatment (55 papers), Liver Disease and Transplantation (50 papers) and Hepatitis C virus research (32 papers). Guy Neff is often cited by papers focused on Liver Disease Diagnosis and Treatment (55 papers), Liver Disease and Transplantation (50 papers) and Hepatitis C virus research (32 papers). Guy Neff collaborates with scholars based in United States, United Kingdom and Germany. Guy Neff's co-authors include Nyingi Kemmer, Stephen A. Harrison, Eugene R. Schiff, Marzia Montalbano, Andreas G. Tzakis, Arun J. Sanyal, William P. Forbes, Enoch Bortey, Nathan M. Bass and Audrey L. Shaw and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Guy Neff

134 papers receiving 4.8k citations

Hit Papers

Rifaximin Treatment in Hepatic Encephalopathy 2010 2026 2015 2020 2010 2021 2023 2020 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rifaximin Treatment in Hepatic Encephalopathy
    2010 848 citations Arun J. Sanyal, Guy Neff et al. profile →
  2. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
    2021 255 citations Stephen A. Harrison, Guy Neff et al. profile →
  3. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
    2023 234 citations Stephen A. Harrison, Rebecca Taub et al. profile →
  4. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
    2020 218 citations Stephen A. Harrison, Guy Neff et al. profile →
  5. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
    2024 217 citations Mandy Fraessdorf, Guy Neff et al. profile →
  6. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
    2023 146 citations Stephen A. Harrison, Juan P. Frías et al. profile →
  7. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
    2025 19 citations Mazen Noureddin, Guy Neff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guy Neff United States 35 3.0k 2.7k 1.6k 687 577 141 4.9k
Arie Regev United States 34 2.8k 0.9× 2.6k 1.0× 936 0.6× 295 0.4× 335 0.6× 95 4.7k
Franco Filipponi Italy 39 1.3k 0.4× 2.1k 0.8× 3.2k 2.0× 706 1.0× 623 1.1× 230 5.3k
Curtis K. Argo United States 34 3.3k 1.1× 2.4k 0.9× 1.2k 0.7× 1.1k 1.6× 372 0.6× 81 4.4k
P. Michielsen Belgium 34 2.1k 0.7× 1.5k 0.6× 662 0.4× 392 0.6× 472 0.8× 219 4.0k
Sébastien Dharancy France 37 4.6k 1.5× 3.4k 1.3× 1.9k 1.2× 1.2k 1.7× 536 0.9× 159 6.7k
Massimo Rossi Italy 36 1.6k 0.5× 2.6k 1.0× 2.1k 1.3× 97 0.1× 468 0.8× 280 4.8k
Eberhard L. Renner Canada 38 1.9k 0.6× 2.8k 1.0× 2.0k 1.2× 90 0.1× 398 0.7× 160 4.5k
Antoine Hadengue Switzerland 52 5.1k 1.7× 6.1k 2.3× 4.0k 2.4× 394 0.6× 533 0.9× 227 9.3k
David H. Van Thiel United States 40 1.7k 0.6× 3.3k 1.2× 3.3k 2.0× 108 0.2× 259 0.4× 128 5.5k
Mark Muthiah Singapore 32 2.5k 0.8× 1.2k 0.5× 636 0.4× 1.0k 1.5× 536 0.9× 184 4.1k

Countries citing papers authored by Guy Neff

Since Specialization
Citations

This map shows the geographic impact of Guy Neff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Neff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Neff more than expected).

Fields of papers citing papers by Guy Neff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Neff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Neff. The network helps show where Guy Neff may publish in the future.

Co-authorship network of co-authors of Guy Neff

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Neff. A scholar is included among the top collaborators of Guy Neff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Neff. Guy Neff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lawitz, Eric, Mandy Fraessdorf, Guy Neff, et al.. (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of Hepatology. 81(5). 837–846. 25 indexed citations
3.
Harrison, Stephen A., Juan P. Frías, Kathryn Jean Lucas, et al.. (2024). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology. 23(1). 103–113. 37 indexed citations
4.
Schattenberg, Jörn M., Guy Neff, Arun J. Sanyal, et al.. (2023). UEG Week 2023 Oral Presentations. United European Gastroenterology Journal. 11(S8). 9–200. 1 indexed citations
5.
Harrison, Stephen A., et al.. (2022). Biomarkers, imaging and safety in resmetirom 52 week non-cirrhotic NASH phase 3 clinical trial, completed open-label arm of maestro-NAFLD-1. Digestive and Liver Disease. 54. S48–S48. 1 indexed citations
6.
Alsina, Angel, et al.. (2012). Epidemiology of Hepatocellular Carcinoma in Florida – Part I: A Statewide Report. SHILAP Revista de lepidopterología. 2 indexed citations
7.
Husain, Khalid, et al.. (2012). Complications in paediatric liver transplant from Kuwait when transplanted abroad. Arab Journal of Gastroenterology. 13(4). 178–179. 1 indexed citations
8.
Mathur, Abhishek, John P. Leone, Nyingi Kemmer, et al.. (2012). Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB. 15(7). 504–510. 66 indexed citations
9.
Neff, Guy, et al.. (2011). The current economic burden of cirrhosis.. PubMed Central. 7(10). 661–71. 124 indexed citations
10.
Neff, Guy, et al.. (2010). Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. Liver Transplantation. 16(8). 960–963. 28 indexed citations
11.
Neff, Guy. (2010). Factors Affecting Compliance and Persistence with Treatment for Hepatic Encephalopathy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(5P2). 22S–7S. 16 indexed citations
12.
Kemmer, Nyingi, et al.. (2008). Seroepidemiology of hepatitis A virus in Kuwait. World Journal of Gastroenterology. 15(1). 102–102. 16 indexed citations
13.
Kemmer, Nyingi & Guy Neff. (2007). Managing chronic hepatitis C in the difficult‐to‐treat patient. Liver International. 27(10). 1297–1310. 18 indexed citations
14.
Montalbano, Marzia, et al.. (2005). Fulminant Hepatic Failure from Herpes Simplex Virus: Post Liver Transplantation Acyclovir Therapy and Literature Review. Transplantation Proceedings. 37(10). 4393–4396. 28 indexed citations
15.
Nishida, Seigo, Jeffrey J. Gaynor, Noboru Nakamura, et al.. (2005). Refractory Ascites After Liver Transplantation: An Analysis of 1058 Liver Transplant Patients at a Single Center. American Journal of Transplantation. 6(1). 140–149. 34 indexed citations
16.
17.
Neff, Guy, Christopher O’Brien, Jose Nery, et al.. (2004). Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transplantation. 10(12). 1497–1503. 47 indexed citations
18.
Montalbano, Marzia, Guy Neff, Noriyo Yamashiki, et al.. (2004). A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications. Transplantation. 78(2). 264–268. 95 indexed citations
19.
Santos, Edgardo S., et al.. (2003). Primary Hepatic Non-Hodgkin's Lymphomas: Case Report and Review of The Literature. The American Journal of Gastroenterology. 98(12). 2789–2793. 34 indexed citations
20.
Ragni, Margaret V., Steven H. Belle, Guy Neff, et al.. (2003). Survival of Human Immunodeficiency Virus–Infected Liver Transplant Recipients. The Journal of Infectious Diseases. 188(10). 1412–1420. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arie Regev Breakdown of academic impact, for papers by Franco Filipponi Breakdown of academic impact, for papers by Curtis K. Argo Breakdown of academic impact, for papers by P. Michielsen Breakdown of academic impact, for papers by Sébastien Dharancy Breakdown of academic impact, for papers by Massimo Rossi Breakdown of academic impact, for papers by Eberhard L. Renner Breakdown of academic impact, for papers by Antoine Hadengue Breakdown of academic impact, for papers by David H. Van Thiel Breakdown of academic impact, for papers by Mark Muthiah
Rankless by CCL
2026